Table of Contents
HIGHLIGHTS ……………………………………………………………………………………………….3
NEW CHOLESTEROL GUIDELINES AND OLD LDL-C GOALS …………………………………..6
PERCENT OF STATIN INTOLERANT AND NHANES DATA………………………………………7
PERCENT NOT MEETING GOAL AND PROJECTED USAGE – 2O PREVENTION ……………8
PERCENT NOT MEETING GOAL AND PROJECTED USAGE – 1O PREVENTION ……………9
PERCENT NOT MEETING GOAL AND PROJECTED USAGE – STATIN INTOLERANT ….. 10
USAGE OF PCSK9 VERSUS CETP INHIBITORS………………………………………………… 11
HeFH AND HIGH LDL-C PATIENTS ………………………………………………………………… 15
USAGE PRIOR TO PCSK9 OUTCOMES STUDIES ……………………………………………….. 17
PRIMARY CARE PROJECTIONS …………………………………………………………………….. 18
COMPLIANCE ……………………………………………………………………………………………. 21
IMPACT OF POSSIBLE COGNITIVE EFFECTS …………………………………………………… 22
INJECTION DEVICES ………………………………………………………………………………….. 23
Table: Summary of Internist/Lipidologist/Diabetologist Projection of PCSK9/CETP Inhibitor Usage by Risk Group in Various Scenarios